{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:27:13Z","timestamp":1793957233229,"version":"4.8.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.msard.2026.107904","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:39:04Z","timestamp":1788968344000},"page":"107904","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and safety of autologous hematopoietic stem cell transplantation (AHSCT) versus alemtuzumab in multiple sclerosis: Systematic review and individual patient data meta-analysis"],"prefix":"10.1016","volume":"115","author":[{"given":"Naima","family":"Kebir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salem","family":"Waleed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef A.EL","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Emad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huthaifah","family":"Ayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsayed S.","family":"Moubarak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toka Aziz","family":"El-Ramly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5255-892X","authenticated-orcid":false,"given":"Omar Fayez","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.msard.2026.107904_bib0001","doi-asserted-by":"crossref","first-page":"E1574","DOI":"10.1212\/WNL.0000000000011545","article-title":"Safety of Alemtuzumab and autologous hematopoietic stem cell transplantation compared to noninduction therapies for multiple sclerosis","volume":"96","author":"Alping","year":"2021","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2026.107904_bib0002","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/ene.14324","article-title":"Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab","volume":"27","author":"Boffa","year":"2020","journal-title":"Eur. J. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2026.107904_bib0003","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1177\/1352458520914818","article-title":"Autologous hematopoietic stem cell transplantation following alemtuzumab therapy in aggressive multiple sclerosis: a report of three cases","volume":"27","author":"Boffa","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107904_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105414","article-title":"Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: sustained improvement in cognition and quality of life","volume":"82","author":"Braun","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2026.107904_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-083582","article-title":"Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial","volume":"14","author":"Brittain","year":"2024","journal-title":"BMJ Open."},{"issue":"5","key":"10.1016\/j.msard.2026.107904_bib0006","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1398-9995.2009.01973.x","article-title":"Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions","volume":"64","author":"Broek","year":"2009","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.msard.2026.107904_bib0007","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2014.17986","article-title":"Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis","volume":"313","author":"Burt","year":"2015","journal-title":"JAMA, J. Am. Med. Assoc."},{"issue":"5","key":"10.1016\/j.msard.2026.107904_bib0008","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00415-021-10820-2","article-title":"Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis","volume":"269","author":"Burt","year":"2022","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2026.107904_bib0009","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1177\/1352458520985238","article-title":"Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with \u2018aggressive\u2019 multiple sclerosis","volume":"27","author":"Das","year":"2021","journal-title":"Mult. Scler. J."},{"issue":"2","key":"10.1016\/j.msard.2026.107904_bib0010","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/0145445516673998","article-title":"Intercoder reliability and validity of WebPlotDigitizer in extracting graphed data","volume":"41","author":"Drevon","year":"2017","journal-title":"Behav. Modif."},{"issue":"10","key":"10.1016\/j.msard.2026.107904_bib0011","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1007\/s00415-019-09424-8","article-title":"Outcomes after fingolimod to alemtuzumab treatment shift in relapsing\u2013remitting MS patients: a multicentre cohort study","volume":"266","author":"Frau","year":"2019","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107904_bib0012","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","article-title":"A new improved graphical and quantitative method for detecting bias in meta-analysis","volume":"16","author":"Furuya-Kanamori","year":"2018","journal-title":"Int. J. Evid. Based. Healthc."},{"issue":"5","key":"10.1016\/j.msard.2026.107904_bib0013","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/art.43072","article-title":"Autologous nonmyeloablative hematopoietic stem cell transplantation for diffuse cutaneous systemic sclerosis: identifying disease risk factors for toxicity and long-term outcomes in a prospective, single-arm trial","volume":"77","author":"Georges","year":"2025","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.msard.2026.107904_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-82196-y","article-title":"New autoimmune disorder development after immune reconstitution therapy for multiple sclerosis","volume":"14","author":"Giedraitien\u0117","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.msard.2026.107904_bib0015","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12974-020-01847-9","article-title":"Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis","volume":"17","author":"Gilmore","year":"2020","journal-title":"J. Neuroinflammation."},{"issue":"9","key":"10.1016\/j.msard.2026.107904_bib0016","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/1352458517703193","article-title":"No evident disease activity\u201d: the use of combined assessments in the management of patients with multiple sclerosis","volume":"23","author":"Giovannoni","year":"2017","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2026.107904_bib0017","doi-asserted-by":"crossref","first-page":"520","DOI":"10.5195\/jmla.2021.1260","article-title":"EndNote 20 desktop version","volume":"109","author":"Gotschall","year":"2021","journal-title":"J. Med. Libr. Assoc."},{"issue":"2","key":"10.1016\/j.msard.2026.107904_bib0018","article-title":"PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open synthesis","volume":"18","author":"Haddaway","year":"2022","journal-title":"Campbell. Syst. Rev."},{"issue":"6","key":"10.1016\/j.msard.2026.107904_bib0019","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/acn3.51366","article-title":"aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis","volume":"8","author":"H\u00e4u\u00dfler","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2026.107904_bib0020","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s10067-017-3954-5","article-title":"Safety profile of autologous hematopoietic stem cell mobilization and transplantation in patients with systemic sclerosis","volume":"37","author":"Helbig","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.msard.2026.107904_bib0021","series-title":"Cochrane Handbook for Systematic Reviews of Interventions: cochrane Book Series. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series","first-page":"1","author":"Higgins","year":"2008"},{"issue":"2","key":"10.1016\/j.msard.2026.107904_bib0022","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: q statistic or I2 index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychol. Methods"},{"issue":"4","key":"10.1016\/j.msard.2026.107904_bib0023","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1474-4422(17)30007-8","article-title":"Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study","volume":"16","author":"Kalincik","year":"2017","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.msard.2026.107904_bib0024","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1001\/jamaneurol.2023.1184","article-title":"Comparative effectiveness of autologous hematopoietic stem cell transplant vs Fingolimod, Natalizumab, and Ocrelizumab in highly active relapsing-remitting multiple sclerosis","volume":"80","author":"Kalincik","year":"2023","journal-title":"JAMa Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107904_bib0025","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/brain\/awaf286","article-title":"Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis","volume":"149","author":"Kalincik","year":"2026","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.msard.2026.107904_bib0026","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2026.107904_bib0027","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/cei.13208","article-title":"Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis","volume":"194","author":"Li","year":"2018","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2026.107904_bib0028","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC. Med. Res. Methodol."},{"key":"10.1016\/j.msard.2026.107904_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106542","article-title":"Comparative analysis of five-year clinical outcomes of autologous hematopoietic stem cell transplantation and alemtuzumab in multiple sclerosis patients","volume":"100","author":"Manazo\u011flu","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2026.107904_bib0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res. Synth. Methods"},{"issue":"4","key":"10.1016\/j.msard.2026.107904_bib0031","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/13524585251315363","article-title":"Patient-reported outcomes of quality of life before and after autologous hematopoietic stem cell transplantation for multiple sclerosis","volume":"31","author":"Mitrache Desaga","year":"2025","journal-title":"Mult. Scler. J."},{"issue":"7","key":"10.1016\/j.msard.2026.107904_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS. Med."},{"issue":"10","key":"10.1016\/j.msard.2026.107904_bib0033","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","author":"Munn","year":"2019","journal-title":"JBI. Evid. Synth."},{"issue":"3","key":"10.1016\/j.msard.2026.107904_bib0034","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41582-024-01050-x","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT","volume":"21","author":"Muraro","year":"2025","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107904_bib0035","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/ana.27247","article-title":"Effectiveness of autologous hematopoietic stem cell transplantation versus Alemtuzumab and Ocrelizumab in relapsing multiple sclerosis: a single center cohort study","volume":"98","author":"Muraro","year":"2025","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2026.107904_bib0036","doi-asserted-by":"crossref","first-page":"E890","DOI":"10.1212\/WNL.0000000000012449","article-title":"Autologous hematopoietic stem cell transplantation in active multiple sclerosis: a real-world case series","volume":"97","author":"Nicholas","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2026.107904_bib0037","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"issue":"4","key":"10.1016\/j.msard.2026.107904_bib0038","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3390\/jcm11040942","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis patients: monocentric case series and systematic review of the literature","volume":"11","author":"Patti","year":"2022","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.msard.2026.107904_bib0039","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2026.107904_bib0040","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1007\/s00415-018-9070-x","article-title":"No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study","volume":"265","author":"Prosperini","year":"2018","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107904_bib0041","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029082","article-title":"Autologous hematopoietic stem cell transplantation in the treatment of multiple sclerosis","volume":"9","author":"Rush","year":"2019","journal-title":"Cold. Spring. Harb. Perspect. Med."},{"issue":"5","key":"10.1016\/j.msard.2026.107904_bib0042","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.3390\/jcm12051768","article-title":"Alemtuzumab-related lymphocyte subset dynamics and disease activity or autoimmune adverse events: real-world evidence","volume":"12","author":"Signoriello","year":"2023","journal-title":"J. Clin. Med."},{"issue":"9","key":"10.1016\/j.msard.2026.107904_bib0043","doi-asserted-by":"crossref","first-page":"e3392","DOI":"10.1210\/clinem\/dgaa453","article-title":"Development of autoimmune thyroid disease in multiple sclerosis patients Post-Alemtuzumab improves treatment response","volume":"105","author":"Sovetkina","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.msard.2026.107904_bib0044","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.msard.2026.107904_bib0045","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/jnnp-2022-328797","article-title":"Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT","volume":"93","author":"Stokke Kvistad","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2026.107904_bib0046","series-title":"In: StatPearls [Internet]","article-title":"Multiple Sclerosis","author":"Tafti","year":"2024"},{"key":"10.1016\/j.msard.2026.107904_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105096","article-title":"Autologous hematopoietic stem cell transplantation is superior to alemtuzumab in patients with highly active relapsing multiple sclerosis and severe disability","volume":"80","author":"Vaisvilas","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2026.107904_bib0048","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/jnnp-2020-323992","article-title":"Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing\u2013remitting multiple sclerosis: an observational study","volume":"92","author":"Zhukovsky","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.msard.2026.107904_bib0049","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s40263-020-00749-x","article-title":"Efficacy and safety of Alemtuzumab through 9 years of follow-up in patients with highly active disease: post hoc analysis of CARE-MS I and II patients in the TOPAZ extension study","volume":"34","author":"Ziemssen","year":"2020","journal-title":"CNS. Drugs"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826009399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826009399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:43:40Z","timestamp":1793954620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826009399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":49,"alternative-id":["S2211034826009399"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107904","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of autologous hematopoietic stem cell transplantation (AHSCT) versus alemtuzumab in multiple sclerosis: Systematic review and individual patient data meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107904","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107904"}}